Biodel Prices 4.482M Share Public Offering of Common Stock at $4.35; Tuesday's Close Price Was $4.76
Biodel (Nasdaq: BIOD) today announced the pricing of an underwritten public offering of 4,482,760 shares of its common stock at a public offering price of $4.35 per share. All of the shares are being sold by Biodel. The offering is expected to close on June 24, 2013, subject to customary closing conditions. Biodel has also granted the underwriters a 30-day option to purchase up to an additional 672,414 shares to cover overallotments, if any.
William Blair & Company, L.L.C. is acting as the sole book-running manager of the offering and Ladenburg Thalmann & Co. Inc. is acting as co-manager for the offering.
The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission. Biodel will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Biodel, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement, copies of which may be obtained, when available, from William Blair & Company, L.L.C. at 222 West Adams Street, Chicago, IL 60606, Attention: Prospectus Department, by telephone at (800) 621-0687, or by email at firstname.lastname@example.org.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel Inc. develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.